About Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 (GNB2) is a protein
from Homo sapiens identified by UniProt accession
P62879, 340 residues long.
MolForge cross-references it against 0 known binders and
91 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 |
| UniProt accession | P62879 |
| Gene | GNB2 |
| Organism | Homo sapiens |
| Length | 340 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (91)
Diseases linked to this target (Open Targets).
- familial sick sinus syndrome · score 0.45
- hematocrit · score 0.42
- hemoglobin measurement · score 0.38
- complex neurodevelopmental disorder · score 0.37
- mean corpuscular hemoglobin concentration · score 0.36
- erythrocyte count · score 0.34
- breast adenocarcinoma · score 0.28
- endometrial cancer · score 0.28
- Global developmental delay · score 0.27
- head and neck squamous cell carcinoma · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P62879-F1 | alphafold | PREDICTED | 96.90 | — |
Amino-acid sequence (340 residues)
MSELEQLRQE AEQLRNQIRD ARKACGDSTL TQITAGLDPV GRIQMRTRRT LRGHLAKIYA MHWGTDSRLL VSASQDGKLI IWDSYTTNKV HAIPLRSSWV MTCAYAPSGN FVACGGLDNI CSIYSLKTRE GNVRVSRELP GHTGYLSCCR FLDDNQIITS SGDTTCALWD IETGQQTVGF AGHSGDVMSL SLAPDGRTFV SGACDASIKL WDVRDSMCRQ TFIGHESDIN AVAFFPNGYA FTTGSDDATC RLFDLRADQE LLMYSHDNII CGITSVAFSR SGRLLLAGYD DFNCNIWDAM KGDRAGVLAG HDNRVSCLGV TDDGMAVATG SWDSFLKIWN
Explore Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets